A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Summary

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.

Interventions

• LY4405094 · DRUG

  Administered intravenously (IV)

• LY4405094 · DRUG

  Administered Subcutaneously (SC)

• Placebo · DRUG

  Administered IV

• Placebo · DRUG

  Administered SC

• Florbetapir F18 · OTHER

  Administered IV

• Florbetaben F 18 · OTHER

  Administered IV

Published eligibility criteria

Verbatim from the registry. Only the site can decide how these apply to a specific patient.

Inclusion Criteria:

* Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study.

Exclusion Criteria:

* Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094.
* Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

Sites (16)

• CenExel ACT, Anaheim, California
• Irvine Clinical Research, Irvine, California
• Collaborative Neuroscience Network - CNS, Los Alamitos, California
• Fortrea Clinical Research Unit, Daytona Beach, Florida
• K2 Medical Research - The Villages, Lady Lake, Florida
• K2 Medical Research, Maitland, Florida
• Charter Research, Orlando, Florida
• Progressive Medical Research, Port Orange, Florida
• Alzheimer's Research and Treatment Center, Stuart, Florida
• K2 Medical Research - Tampa, Tampa, Florida
• Charter Research, The Villages, Florida
• Accel Research Sites - NeuroStudies Clinical Research Unit, Decatur, Georgia
• QUEST Research Institute, Farmington Hills, Michigan
• Xuanwu Hospital Capital Medical University, Beijing, China
• The University of Tokyo Hospital, Bunkyō City, Japan
• National Center for Geriatrics and Gerontology, Ōbu, Japan